Recursion Pharmaceuticals granted inducement RSU awards to 17 new employees under its 2024 Inducement Equity Incentive Plan. The awards are tied to recent hiring activity and are intended as ...

Recursion Pharmaceuticals Inc .股价创下新的52周低点，收盘价为3.53美元，距离其52周绝对最低点3.54美元仅差几分钱。这一里程碑标志着该公司的重大下滑， InvestingPro 数据显示，过去一年该股价下跌了55.52%。根据InvestingPro的公允价值评估，该股票在当前水平略显低估。这家以通过机器学习和自动化进行创新药物发现而闻名的生物制药公司在市场上 ...

If you are trying to figure out whether Recursion Pharmaceuticals is attractively priced or a high risk speculation, a useful starting point is understanding what the current market price might be ...

Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced that on February 6, 2026, the Compensation Committee of Recursion's Board of ...

根据提交给美国证券交易委员会的Form 4文件显示，董事Blake Borgeson于2026年2月3日出售了220,000股 Recursion Pharmaceuticals Inc (NASDAQ:RXRX) ...

Monday - Friday, 6:00 - 7:00 PM ET In a Friday interview with CNBC's Jim Cramer, Recursion Pharmaceuticals CEO Chris Gibson discussed how his company is using artificial intelligence and machine ...

Everything touching artificial intelligence (AI) is hot right now, so it's no surprise that the biotech Recursion Pharmaceuticals (NASDAQ: RXRX) could be positioned to ride the ongoing wave of hype to ...

Guidance remains unchanged, with management projecting "over $100 million in partnership inflows by the end of 2026" and targeting a cash burn below $390 million in 2026. The company anticipates a ...

Recursion Pharmaceuticals presents a compelling investment opportunity due to its AI-driven drug discovery platform, solid financials, and diverse pipeline, setting it apart from competitors like ...